B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy

The Renal Therapies Division of B. Braun Medical Inc. (B. Braun) announced today the availability of the Plasmat™ Futura System for H.E.L.P.®  LDL Apheresis therapy. This addition to B. Braun's existing H.E.L.P.® therapy provides a more easy-to-use system for clinicians to administer the most effective care to patients with severe hypercholesterolemia.

H.E.L.P.®  therapy (Heparin-induced Extracorporeal Lipoprotein Precipitation) is a blood cleansing procedure for the long-term management of patients with severe, congenital lipid disorders that cannot be adequately treated with diet modification or drugs.

"The addition of the Plasmat™ Futura Apheresis system to our existing H.E.L.P.® therapy system exemplifies B. Braun's commitment to providing clinicians with innovative systems that help get their jobs done with more convenience and flexibility," said Samuel Amory, Vice President, Medical Technology Division for B. Braun Medical Inc. "LDL Apheresis therapy is a complex therapy and the Plasmat™ Futura helps to streamline treatment."  

Designed to be compact and easy to use, the Plasmat™ Futura system provides built-in convenience for maximum mobility and flexibility. In addition, the Plasmat™ Futura features a state-of-the-art user interface and does not require an on-site water treatment system, both improvements over the previous H.E.L.P.® system.

"The Plasmat™ Futura LDL Apheresis machine is the first promising procedure that has drastically cut my LDL by more than 60 percent," said Patrika Wallach-Knickle, a patient of Massachusetts General Hospital. "All it requires is a commitment of two mornings a month to sit and relax while the machine does the work. This small commitment is nothing compared to the benefits of seeing my small child grow up. I am very grateful for the B. Braun Plasmat™ Futura LDL Apheresis machine."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 20). B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy. News-Medical. Retrieved on May 19, 2024 from https://www.news-medical.net/news/20110715/B-Braun-adds-Plasmat-Futura-System-to-HELP-LDL-Apheresis-therapy.aspx.

  • MLA

    B. Braun Melsungen AG. "B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy". News-Medical. 19 May 2024. <https://www.news-medical.net/news/20110715/B-Braun-adds-Plasmat-Futura-System-to-HELP-LDL-Apheresis-therapy.aspx>.

  • Chicago

    B. Braun Melsungen AG. "B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy". News-Medical. https://www.news-medical.net/news/20110715/B-Braun-adds-Plasmat-Futura-System-to-HELP-LDL-Apheresis-therapy.aspx. (accessed May 19, 2024).

  • Harvard

    B. Braun Melsungen AG. 2019. B. Braun adds Plasmat Futura System to H.E.L.P. LDL Apheresis therapy. News-Medical, viewed 19 May 2024, https://www.news-medical.net/news/20110715/B-Braun-adds-Plasmat-Futura-System-to-HELP-LDL-Apheresis-therapy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021